- New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session
- Preclinical data on ARQ-234, CD200R agonist, for the treatment of atopic dermatitis
- Additional presentation of the consistent tolerability profile of topical roflumilast in psoriasis, seborrheic dermatitis, and atopic dermatitis
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, which will take place in Chicago, IL from June 8-10, 2024. Among these presentations will be new long-term safety and efficacy data for roflumilast cream 0.15% in patients ≥6 years of age with mild to moderate atopic dermatitis, and an encore of preclinical data on ARQ-234, a CD200 receptor agonist the Company is investigating for atopic dermatitis.
In addition, the Company will present investigator- and patient-rated local tolerability data evaluating topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
